Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emerfetamab (AMG 673) in Relapsed/Refractory AML
NCT03224819Phase 1Terminated
- Sponsor
- Amgen
- Start
- Sep 2017
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of emerfetamab in acute myeloid leukemia (AML) (2 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events and Number of Participants With Dose-limiting Toxicities. Started Sep 2017; status: terminated.
02
Drugs
emerfetamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03224819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224819.